Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush
By Amit Summan, Arindam Nandi, Sarang Deo, Ramanan Laxminarayan
Proceedings of NY Academy of Sciences | July 2021
DOI
nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/nyas.14657
Citation
Summan, Amit., Nandi, Arindam., Deo, Sarang., Laxminarayan, Ramanan. Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush Proceedings of NY Academy of Sciences nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/nyas.14657.
Copyright
Proceedings of NY Academy of Sciences, 2021
Share:
Abstract
Only an estimated 62% of Indian children under the age of 2 years are fully immunized.We examined the association between India’s Mission Indradhanush (MI)—a periodic intensification of the routine immunization program— which was implemented in phases across districts between March 2015 and July 2017, and routine vaccination coverage and timeliness among children. We used data from a 2015 to 2016 national survey of children (n = 29,532) and employed difference-in-difference regressions to examine binary indicators of receipt of 11 vaccines and whether vaccines were received at recommended ages. The full immunization rate was 27% higher among children under 2 years old residing in MI phase 1 and 2 districts (intervention group) as compared with those residing elsewhere (control group). The rate of receiving all vaccines at recommended ages was 8% higher in the intervention group. Receiving doses of oral polio vaccine (OPV) birth dose, OPV dose 1 (OPV1), OPV2, OPV3, bacillus Calmette– Guérin, and hepatitis B birth dose vaccines were 9%, 9%, 11%, 16%, 5%, and 19% higher in the intervention group than the control group, respectively. More research is required on the cost-effectiveness of investing in MI-type programs as compared with routine immunization

Sarang Deo is a Professor of Operations Management at the Indian School of Business (ISB), where he also serves as the Deputy Dean for Faculty and Research and as the Executive Director of the Max Institute of Healthcare Management (MIHM).

His primary area of research is health care delivery systems. He is interested in investigating the impact of operations decisions on population-level health outcomes. Some of the healthcare contexts that he has studied include the influenza vaccine supply chain and the phenomenon of ambulance diversion in the US, HIV early infant diagnosis networks in sub-Saharan Africa, and formal and informal pathways for tuberculosis (TB) diagnosis in India. He regularly collaborates with international public health funding and implementation agencies such as Bill & Melinda Gates Foundation (BMGF), Clinton Health Access Initiative (CHAI), and PATH for his research. He currently serves as a member of the WHO Strategic and Technical Advisory Group on TB (STAG-TB).

Prior to joining ISB, Professor Deo was an Assistant Professor at the Kellogg School of Management. He holds a PhD from UCLA Anderson School of Management, an MBA from Indian Institute of Management (IIM) Ahmedabad, and a B Tech from the Indian Institute of Technology (IIT) Bombay. Before entering academia, he worked with Accenture as a management consultant.

Sarang Deo
Sarang Deo